# Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema

> **NCT02441907** · PHASE4 · COMPLETED · sponsor: **Unity Health Toronto** · enrollment: 16 (actual)

## Conditions studied

- Diabetic Macular Edema

## Interventions

- **DRUG:** aflibercept

## Key facts

- **NCT ID:** NCT02441907
- **Lead sponsor:** Unity Health Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2018-08
- **Final completion:** 2019-09
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02441907

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02441907, "Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular Edema". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02441907. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*